8-K filed November 10, 2025, 6:59 PM ET ticker DMRA CIK 0001800315

M&A confidence high sentiment neutral materiality 0.90

Galecto acquires Damora, raises ~$285M PIPE, appoints Fairmount-affiliated directors

Damora Therapeutics, Inc.

Galecto acquired Damora Therapeutics; issued 265,309 common shares, 16,366 Series B and 4,241 Series C preferred shares to Damora stockholders.
Concurrent PIPE of ~$285M via sale of 39,641 Series C preferred shares; closing expected Nov 12, 2025.
Board replaced: Anne Prener, David Shapiro, Amy Wechsler resigned; Peter Harwin, Chris Cain, Julianne Bruno (Fairmount) appointed.
Executive retention bonuses: CEO (DKK 2,173,800 target), CFO ($112,500), GC ($161,160); CFO salary increased to $375,000.
Series B & C preferred are non-voting, convertible 1:1,000 into common, subject to stockholder approval and ownership caps.

item 1.01 item 5.03 item 2.01 item 3.02 item 5.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-273342
form_type: 8-K
ticker: DMRA
cik: 0001800315
company_name: Damora Therapeutics, Inc.
filed_at: 2025-11-10T23:59:59+00:00
discovered_at: 2026-05-14T18:02:40.495838+00:00
generated_at: 2026-05-16T22:32:36.041245+00:00
sec_items: ["1.01", "5.03", "2.01", "3.02", "5.02", "7.01", "9.01"]
event_type: m_and_a
sentiment: neutral
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-273342
json_url: https://secwatch.observer/filing/0001193125-25-273342.json
markdown_url: https://secwatch.observer/filing/0001193125-25-273342.md
text_url: https://secwatch.observer/filing/0001193125-25-273342.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1800315/000119312525273342/0001193125-25-273342-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1800315/000119312525273342/d53983d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

9c5a682743c1eb233b78d9774894ed8438b2cbc4

Damora Therapeutics, Inc.: Filed Certificates of Designation for Series B and Series C Preferred Stock, creating new stock series with specific rights and limitations (effective 2025-11-07).

On November 7, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock (the “Certificate of Designation of Series B Preferred Stock”) and a Certificate of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock (the “Certificate of Designation of Series C Preferred Stock,” and together with the Certificate of Designation of Series B Preferred Stock, the “Certificates of Designation”) in connection with the Merger and the Financing referenced in Item 1.01 above.

SEC 8-K Item 5.03/5.05/5.06 confidence 0.9 SEC evidence

80cb62a3192508a9b687b9b76da5ad3ff04de96e

Damora Therapeutics, Inc. completed an acquisition involving Damora Therapeutics, Inc. (closed 2025-11-10).

On November 10, 2025, the Company completed its business combination with Damora.

SEC 8-K Item 2.01/5.01 confidence 0.9 SEC evidence

Comparable filings

APAD

Enhanced Group completes de-SPAC merger with Enhanced Ltd; redemptions of $201.7M

Enhanced Group Inc. May 8, 2026, 7:59 PM ET m_and_a Items 1.01, 2.01, 5.06, 3.02, 9.01, 4.01, 3.01, 3.03, 5.01, 5.02, 5.03, 5.05, 7.01

same fact type: governance_change, ma_transaction same SEC item: 1.01, 2.01, 3.02, 5.02, 5.03, 7.01, 9.01 same event type: m_and_a similar materiality

This filing

On November 7, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock (the “Certificate of Designation of Series B Preferred Stock”) and a Certificate of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock (the “Certificate of Designation of Series C Preferred Stock,” and together with the Certificate of Designation of Series B Preferred Stock, the “Certificates of Designation”) in connection with the Merger and the Financing referenced in Item 1.01 above.

Comparable filing

As a result of the Business Combination, the Company ceased being a shell company

Filing page SEC filing

CHRN

Ekso Bionics completes reverse merger with Applied Digital subsidiary; renames to ChronoScale Corp.

EKSO BIONICS HOLDINGS, INC. May 5, 2026, 7:59 PM ET m_and_a Items 1.01, 2.01, 2.02, 3.02, 3.03, 4.01, 5.01, 5.02, 5.03, 9.01

same fact type: governance_change, ma_transaction same SEC item: 1.01, 2.01, 3.02, 5.02, 5.03, 9.01 same event type: m_and_a similar materiality

This filing

On November 7, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock (the “Certificate of Designation of Series B Preferred Stock”) and a Certificate of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock (the “Certificate of Designation of Series C Preferred Stock,” and together with the Certificate of Designation of Series B Preferred Stock, the “Certificates of Designation”) in connection with the Merger and the Financing referenced in Item 1.01 above.

Comparable filing

on May 1, 2026, the Company filed the Second Amended and Restated Articles of Incorporation (the “A&R Articles”) with the Secretary of State of the State of Nevada with a delayed effective date and time of 3:00 a.m. (Eastern Time) on May 5, 2026.

Filing page SEC filing

GYRE

Gyre Therapeutics completes $300M all-stock acquisition of Cullgen; appoints Ying Luo as CEO

GYRE THERAPEUTICS, INC. May 4, 2026, 7:59 PM ET m_and_a Items 2.01, 5.03, 1.01, 3.02, 3.03, 5.02, 7.01, 9.01

same fact type: governance_change, ma_transaction same SEC item: 1.01, 2.01, 3.02, 5.02, 5.03, 7.01, 9.01 same event type: m_and_a similar materiality

This filing

On November 7, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock (the “Certificate of Designation of Series B Preferred Stock”) and a Certificate of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock (the “Certificate of Designation of Series C Preferred Stock,” and together with the Certificate of Designation of Series B Preferred Stock, the “Certificates of Designation”) in connection with the Merger and the Financing referenced in Item 1.01 above.

Comparable filing

The Company has filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Company Preferred Stock (the “Certificate of Designation”) in connection with the Merger referenced in Item 1.01 above.

Filing page SEC filing

ESAB

ESAB completes $1.45B acquisition of Eddyfi Technologies

ESAB Corp June 2, 2026, 6:41 AM ET m_and_a Items 2.01, 3.02, 5.03, 3.03, 7.01, 8.01, 9.01

same fact type: governance_change, ma_transaction same SEC item: 2.01, 3.02, 5.03, 7.01, 9.01 same event type: m_and_a similar materiality

This filing

On November 7, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock (the “Certificate of Designation of Series B Preferred Stock”) and a Certificate of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock (the “Certificate of Designation of Series C Preferred Stock,” and together with the Certificate of Designation of Series B Preferred Stock, the “Certificates of Designation”) in connection with the Merger and the Financing referenced in Item 1.01 above.

Comparable filing

On June 1, 2026, the Company filed the Certificate of Designations with the Delaware Secretary of State to establish the preferences, limitations and relative rights of its 6.50% Series A Mandatory Convertible Preferred Stock (the “ Series A Mandatory Convertible Preferred Stock ”), which became effective upon filing.

Filing page SEC filing

OCFC

OceanFirst closes acquisition of Flushing Financial; issues shares to Warburg Pincus

OCEANFIRST FINANCIAL CORP June 1, 2026, 5:19 PM ET m_and_a Items 1.01, 3.02, 2.01, 2.03, 3.03, 5.02, 5.03, 7.01, 9.01

same fact type: ma_transaction same SEC item: 1.01, 2.01, 3.02, 5.02, 5.03, 7.01, 9.01 same event type: m_and_a similar materiality

This filing

On November 10, 2025, the Company completed its business combination with Damora.

Comparable filing

of Flushing (“ Flushing Common Stock ”) issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, was converted into the right to receive 0.85 of a share (the “ Exchange Ratio ”) of common stock, par value $0.01 per share, of OceanFirst (“ OceanFirst Common Stock ” and such consideration, the “ Merger Consideration ”).

Filing page SEC filing

Enviri II Corp

New Enviri completes spin-off; starts trading June 2 under NVRI; ~$1.2B revenue, ~$140M EBITDA

Enviri II Corp June 1, 2026, 5:18 PM ET m_and_a Items 1.01, 2.03, 3.03, 5.03, 5.01, 5.02, 5.05, 7.01, 9.01

same fact type: governance_change, ma_transaction same SEC item: 1.01, 5.02, 5.03, 7.01, 9.01 same event type: m_and_a similar materiality

This filing

On November 7, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock (the “Certificate of Designation of Series B Preferred Stock”) and a Certificate of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock (the “Certificate of Designation of Series C Preferred Stock,” and together with the Certificate of Designation of Series B Preferred Stock, the “Certificates of Designation”) in connection with the Merger and the Financing referenced in Item 1.01 above.

Comparable filing

In connection with the Spin-Off, the Board adopted the Code of Conduct, a copy of which is available on New Enviri’s website at www.enviri.com.

Filing page SEC filing

DVN

Devon completes all-stock merger with Coterra; combined company retains DVN ticker

DEVON ENERGY CORP/DE May 7, 2026, 7:59 PM ET m_and_a Items 2.01, 5.02, 5.03, 7.01, 9.01

same fact type: governance_change, ma_transaction same SEC item: 2.01, 5.02, 5.03, 7.01, 9.01 same event type: m_and_a similar materiality

This filing

On November 7, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock (the “Certificate of Designation of Series B Preferred Stock”) and a Certificate of Designation of Preferences, Rights and Limitations of the Series C Preferred Stock (the “Certificate of Designation of Series C Preferred Stock,” and together with the Certificate of Designation of Series B Preferred Stock, the “Certificates of Designation”) in connection with the Merger and the Financing referenced in Item 1.01 above.

Comparable filing

On May 7, 2026, the Company filed an amendment to the Company’s restated certificate of incorporation (the “ Authorized Share Charter Amendment ”), effective as of such date, increasing the number of authorized shares of Company Common Stock from 1,000,000,000 to 2,000,000,000.

Filing page SEC filing

SHPH

Shuttle Pharma completes merger with United Dogecoin, pivots to crypto, raises $9.55M PIPE

Shuttle Pharmaceuticals Holdings, Inc. May 7, 2026, 7:59 PM ET m_and_a Items 1.01, 2.01, 3.02, 3.03, 5.02, 5.03, 9.01

same fact type: ma_transaction same SEC item: 1.01, 2.01, 3.02, 5.02, 5.03, 9.01 same event type: m_and_a similar materiality

This filing

On November 10, 2025, the Company completed its business combination with Damora.

Comparable filing

On May 6, 2026 (the “ Closing Date ”), Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“ Shuttle ” or “ Acquiror ”), completed its previously announced merger pursuant to an Agreement and Plan of Merger (the “ Merger Agreement ”), entered into on April 30, 2026 by and among the Acquiror, Shuttle Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Shuttle (“ Merger Sub ”) and United Dogecoin Inc., a Delaware corporation (the “ Company ”).

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-25-273342

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.